Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, today announced ...
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...
Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...
Wednesday said the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its COVID-19-Influenza ...
The Therapeutic Goods Administration has given Pfizer's new COVID-19 jab the green light. But what about vaccines from ...
Novavax shares plummet 30% as FDA places clinical hold on COVID-19 and influenza combination vaccine due to serious adverse ...
The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.
Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...
Our goal is to successfully resolve this matter and to start our Phase 3 trial as soon as possible." Data from Novavax's previous COVID-19 and influenza trials have shown no signals for motor ...
FDA places a clinical hold on Novavax's COVID-19-influenza vaccine trials due to a serious adverse event in a Phase 2 participant. Novavax's COVID-19 IND and European approval for its updated ...